Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA-222 (miR-222) is a small non-coding RNA molecule of 20-24 nucleotides encoded by the MIR222 gene located on chromosome X. It functions as a post-transcriptional regulator of gene expression by binding to complementary sequences in the 3'-untranslated regions of target messenger RNAs, leading to translational repression or mRNA degradation. MicroRNA-222 exists as multiple isoforms (isomiRs) varying in length from 21 to 25 nucleotides, with different isoforms showing distinct subcellular localization patterns and biological functions. The longer isoforms (>23 nucleotides) are enriched in the nucleus and associated with apoptosis induction, while various length isoforms demonstrate anti-proliferative effects. MicroRNA-222 regulates multiple cellular processes including cell cycle progression, proliferation, apoptosis, invasion, migration, and differentiation through targeting genes such as p27, MMP1, SOD2, and MEF2C. Its role in cancer is complex and context-dependent, functioning as a tumor suppressor in prostate cancer and oral squamous cell carcinoma while showing different effects in other cancer types. It is also implicated in cardiovascular disease and vascular smooth muscle cell proliferation. The therapeutic potential and biomarker utility of miR-222 are being actively investigated, though isoform-specific effects and context-dependent functions present significant challenges for clinical translation.
MicroRNA-222 regulates target genes through both direct targeting of mRNA 3'-untranslated regions (cis-regulatory mechanism) via imperfect base pairing and indirect mechanisms (trans-regulatory mechanism) by controlling gene expression through targeting upstream regulators. This leads to translational repression or mRNA degradation. Additionally, longer miR-222 isoforms (>23 nucleotides) show dramatic nuclear enrichment and may participate in transcriptional regulation (non-canonical mechanism through nuclear localization).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA-222 (miR-222).